



**LONGEVITY BIOTECHNOLOGY
ASSOCIATION**

We are at the beginning of a revolution
that will **turn ageing into a choice**

We are within striking distance of the first
generation of gerotherapeutics.

Over the last decades we have **mapped, modeled,
and diagnosed the root causes of ageing.**

Geroscientists have **demonstrated that age-
related
decline is not inevitable**



In order to make progress against ageing, **we must first measure it.**



In order to make progress against ageing, **we must dispel snakeoil and amplify real science**

In order to make progress against ageing, **we must experiment in humans with drugs explicitly targeting ageing.**



Introducing the Founding Members







Our Mission:

1. Educate the public, investors, and philanthropists on the promise of gerotherapies
2. Standardise the private geroscience industry and introduce best practices.



We are:

Biotechnology Founders

Investors

Scientists

Medical Professionals

Regulatory Leaders

Scientific Funders



Our Mission:

1. Help the Public See the Big, Gradual Picture
2. Set the Standard for Longevity Companies




Next Presenter

Kristen Fortney

CEO and co-founder of
BioAge



A portrait of a woman with long, straight brown hair, looking directly at the camera with a neutral expression. She is wearing a black sleeveless top and a silver necklace. The background is a blurred indoor setting.

Kristen Fortney

Next Presenter

James Peyer

Founder and CEO of
Cambrian Biopharma



The LBA is being launched to allow **collaboration between the many experts involved in building gerotherapeutics**

Breakthroughs around the world have created new medicines that have the potential to prevent multiple diseases at once, **extending human healthspan**

One of the major challenges in developing gerotherapeutics is around the clinical trials to demonstrate they work



The LBA will help set the standards for clinical trials targeting aging

Treating diseases
reactively

Surrogate biomarker
trials for **enhancing
healthspan**

Long-form
prevention trials

LBA can **accelerate** the maturation of the longevity biotech field by:

- ❑ **Share best practices** in designing and operating gerotherapeutics trials
- ❑ **Foster collaboration and data sharing** across different groups



Longevity Field today



Focus of the
LBA



Next Presenter

Mehmood Khan

CEO of Hevolution

Foundation



Every part of this emerging field has been **catalyzed by direct financing** from **prescient donors and investors**

Those who invest now will support breakthroughs that prevent **the source of most human disease.**

Ageing **touches everything**, and provides funders a rare wedge towards improving **all of human health**



Funding this field now **clears a channel for a pipeline of ageing specific drugs to form**

Financing science and drugs that target ageing directly **multiplies funding impact**

Longevity is still small, but rapidly growing. **Now is the time to dive in.**





**LONGEVITY
BIOTECHNOLOGY
ASSOCIATION**



**LONGEVITY BIOTECHNOLOGY
ASSOCIATION**

**For further information
info@longevitybiotech.org**